Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.62 |
| ▸ | CNR1 | P21554 | 4/20 | 0.62 |
| ▸ | PPARG | P37231 | 2/20 | 0.62 |
| ▸ | PPARD | Q03181 | 2/20 | 0.62 |
| ▸ | PPARA | Q07869 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CETP | P11597 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11466468 | 1.00 | CNR2 (0.62) | CNR2CNR1PPARGPPARDPPARA | |
| SCHEMBL7161352 | 0.88 | CNR2 (0.58) | CNR2CNR1PPARGPPARDPPARA | |
| SCHEMBL20586103 | 0.86 | CNR2 (0.49) | CNR2CNR1PPARGPPARDPPARA | |
| SCHEMBL1427217 | 0.85 | CNR2 (0.83) | CNR2CNR1PPARGPPARDPPARA | |
| SCHEMBL1427219 | 0.85 | CNR2 (0.83) | CNR2CNR1PPARGPPARDPPARA | |
| SCHEMBL8648273 | 0.84 | CNR2 (0.47) | CNR2CNR1PPARGPPARDPPARA | |
| SCHEMBL7772177 | 0.84 | CNR2 (0.47) | CNR2CNR1PPARGPPARDPPARA | |
| SCHEMBL25428215 | 0.83 | CNR2 (0.46) | CNR2CNR1PPARGPPARDPPARA | |
| SCHEMBL10763922 | 0.82 | CNR2 (0.53) | CNR2CNR1PPARGPPARDPPARA | |
| SCHEMBL6635135 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2022-11-10 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-11008334-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200255446-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-08-13 | — | — | US | disclosed |
| CN-110062753-A | Antiviral compounds | 哈普洛根有限责任公司 | 2019-07-26 | — | — | CN | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| EP-3512836-A1 | ANTIVIRAL COMPOUNDS | Haplogen GmbH (AT) | 2019-07-24 | — | — | EP | disclosed |
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-07-03 | — | — | US | disclosed |
| US-20170137463-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2017-05-18 | — | — | US | disclosed |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-13 | — | — | US | disclosed |
| WO-2010003238-A1 | PHASE 2 PROTEIN INDUCING ALKAMIDES | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2010-01-14 | — | — | WO | disclosed |
| WO-2009041786-A2 | PHARMACEUTICAL COMPOSITION COMPRISING INHIBITORS OF CELL ADHESION MOLECULE ISOLATED FROM PIPER LONGUM FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASE | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-04-02 | — | — | WO | disclosed |
| EP-0002735-B1 | PROCESS FOR THE PREPARATION OF PIPERONYLIDENECROTON AMIDES | HAARMANN & REIMER GMBH (DE) | 1980-12-10 | — | — | EP | disclosed |
| EP-0002734-B1 | PROCESS FOR THE PREPARATION OF PIPERONYLIDENECROTON AMIDES | HAARMANN & REIMER GMBH (DE) | 1980-09-17 | — | — | EP | disclosed |
| US-4209446-A | FROM PIPERONAL AND A CROTONIC AMIDE IN PRESENCE OF ALKALI METAL HYDROXIDE AND DIPOLAR APROTIC DILUENT | HAARMAN & REIMER GMBH (DE) | 1980-06-24 | — | — | US | disclosed |
| US-4209445-A | FROM PIPERONAL AND A CROTONIC AMIDE IN PRESENCE OF QUATERNARY AMMONIUM OR PHOSPHONIUM HYDROXIDE OR CROWN ETHER METAL COMPLEX | HAARMAN & REIMER GMBH (DE) | 1980-06-24 | — | — | US | disclosed |
| EP-0002734-A2 | Process for the preparation of piperonylidenecroton amides | HAARMANN & REIMER GMBH (DE) | 1979-07-11 | — | — | EP | disclosed |
| EP-0002735-A2 | Process for the preparation of piperonylidenecroton amides | HAARMANN & REIMER GMBH (DE) | 1979-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | CNR2 2339/4885CNR1 1319/4885PPARG 2454/4885 |
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | PLA2G12A, PLA2G1B, PLA2G4C | CNR2 2681/4885CNR1 1779/4885PPARG 2523/4885 |
| US-20170137463-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | CNR2 3881/4885CNR1 3348/4885PPARG 2681/4885 |
| US-20200255446-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | CNR2 3425/4885CNR1 3237/4885PPARG 841/4885 |
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | CNR2 2355/4885CNR1 3066/4885PPARG 3577/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | CNR2 2339/4885CNR1 1319/4885PPARG 2454/4885 |
| US-11008334-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | CNR2 3425/4885CNR1 3237/4885PPARG 841/4885 |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | CNR2 238/4885CNR1 495/4885PPARG 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.